Amryt Pharma PLC

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded on July 17, 2019 and is headquartered in Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amryt Pharma Plc operates as a holding company with interests in the development and delivery of treatments to help improve the lives of patients with rare and orphan diseases. The company was founded in August 2015 and is headquartered in Dublin, Ireland.

Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT) said it has received positive feedback from the American drug regulator as it seeks sign-off for its Myalept drug for use in patients with partial lipodystrophy (abnormal distribution of fat). In the US, it is currently used to treat complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Amryt Pharma receives positive feedback from the US Food & Drug Administration regarding Myalept

Amryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy

Rare diseases specialist Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said the French authorities have signed off its drug Myalepta for reimbursement. The Ministry of Social Affairs and Health said it will pay for the use of the treatment as an adjunct to diet for those with leptin deficiency with congenital or acquired general lipodystrophy (abnormal fat distribution in the body).

Amryt Pharma says it will receive reimbursement for Myalepta in France

Amryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)

Exercise of Options and Total Voting Rights

Exercise of Warrants & Issue of Ordinary Shares and Total Voting Rights

Amryt Pharma PLC (NASDAQ:AMYT, LON:AMYT) said it has signed an agreement with Medison Pharma Canada, which will distribute the former's Myalepta drug in the country. It completes the multi-regional distribution deal with Medison announced in February for two products, the other being Lojuxta/Juxtapid.

Amryt Pharma inks Canada distribution agreement for Myalepta drug

Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Amryt Pharma PLC (LON:AMYT, NASDAQ:AMYT) said it expects to continue strong sales growth for 2021 after reporting a first underlying profit and strong cash flow for the past year. The biopharma company, which acquires, develops and commercialises novel treatments for rare diseases, generated revenue growth of 18.5% to US$182.6mln for 2020 from its two products on the market, metreleptin as a supplement for people with leptin deficiency and lomitapide, for adults with a rare cholesterol disorder.

Amryt Pharma eyes further growth for 2021 after year of positive cash generation

Amryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021

Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel

Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales

Amryt Granted Orphan Drug Designation by the FDA for AP103

Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia

Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil

Amryt Announces $40m Private Placement with Leading Biotech Investors

Amryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance

AMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA

Amryt and Swixx Sign Distribution Deal for Lojuxta

Notice of Results

Virtual Analyst & Investor Event - Tuesday November 3, 2020

AMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020

AMRYT PHARMA NOTIFICATION OF CANCELLATION OF ADMISSION TO EURONEXT GROWTH

DUBLIN, Ireland, and Boston MA, July 8 2020, Amryt (Nasdaq: AMYT, AIM: AMYT, Euronext Growth: AYP), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, announces that its American Depositary Shares (“ADSs”) are now trading on the Nasdaq Global Select Market (“Nasdaq”) under the symbol AMYT. Each ADS represents five of the Company’s ordinary shares (“Ordinary Shares”).

News for Amryt Pharma PLC Stock (AMYT)